Does Opus Genetics, Inc. (IRD) Pay a Dividend? (2026)

No. There is no dividend on IRD in our data and the yield is 0%. No revenue multiple is informative here, because the roughly $9.9 million trailing figure is a development-cost reimbursement that shrinks as programs complete, not a commercial ramp. What the market is pricing instead is the presbyopia royalty stream if the October 2026 sNDA clears, the LCA5 Phase 3 asset, and the newly de-risked BEST1 program, against roughly 83 million shares and a balance sheet that does not force a near-term raise. Sell-side coverage as of early September 2026 clustered around a mean target near $10.71, with Wedbush at $13 and RBC at $9 while explicitly flagging speculative risk, which is a reasonable description of the spread of outcomes.

This is worth stating plainly rather than hedging: if you are holding IRD for income, it does not provide any. The only way a position in it puts cash in your pocket is if you sell shares.

A dividend is a standing commitment that a board is very reluctant to cut once started, because a cut is read as a signal about the business. Companies therefore wait until profits and free cash flow are durable before starting one, and many never do, preferring buybacks, which can be paused without the same signalling cost.

Retaining cash is not a weakness in itself. A company that can reinvest a dollar at a high return creates more value by keeping it than by paying it out. The question is whether Opus Genetics, Inc. is actually earning that return on what it reinvests, which is a business question, not a dividend question.

Consistent profitability first, then free cash flow that comfortably exceeds what the business needs to keep growing, and then a management view that it has run out of better uses for the money. Those show up in the quarterly numbers well before any announcement, so the results are the place to watch rather than the press releases. We are not predicting whether or when that happens.

The common approach is to hold IRD for the growth exposure and get income from somewhere else in the portfolio, rather than asking one position to do both jobs. That means dividend-paying stocks, dividend ETFs, or short-term bond and Treasury funds, sized so the income side covers what you need.

• Best dividend stocks for individual payers with long records.
• Best dividend ETFs to get a spread of payers in one holding.
• Best ETFs for monthly income if the timing of the cash matters to you.

Walnut is informational and is not an investment adviser. None of these are recommendations.

With no dividend there is no income to report while you hold IRD, so nothing is taxable until you sell. At sale you owe capital-gains tax on the gain, at long-term rates if you held for more than a year. Compared with a dividend payer in a taxable account, which generates a tax bill every year whether you spend the cash or reinvest it, that deferral is a small structural advantage. See how stocks are taxed. This is not tax advice.

There is not one. Opus Genetics, Inc. (IRD) is a total-return holding: it either works through the share price or it does not work. If you own it, own it for that reason, and build the income part of your portfolio elsewhere. For the full picture see the IRD guide. Walnut can show how IRD fits your real portfolio. It is not an investment adviser.